Li-Fraumeni syndrome is a rare autosomal dominant cancer predisposition 
syndrome. The majority of families fulfilling definition of Li-Fraumeni syndrome 
demonstrate inherited abnormalities involving the p53 gene. Cells with 
dysfunctional p53 are predisposed to the development of cancer phenotype. 
Advexin (Introgen Therapeutics Inc., TX, USA) is an adenoviral-based 
experimental therapeutic that provides delivery of wild-type p53 to cancer cells 
and demonstrates anticancer activity following adequate expression of p53. 
Theoretically, correction of p53 function in cancer developing in patients with 
Li-Fraumeni syndrome through treatment with Advexin will provide anti-tumor 
activity. One patient with Li-Fraumeni syndrome has been reported to have 
responded to Advexin. This review will summarize background knowledge of 
Li-Fraumeni syndrome, mechanisms of Advexin and clinical response of cancer to 
Advexin with a focus on Li-Fraumeni syndrome.